الفهرس 
I RON AND P REGNANCYOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
ABSTRACT
Background: Iron deficiency anemia during pregnancy is associated with increased maternal as well as fetal morbidity, including prematurity, low birth-weight and prenatal and infant loss. About 46% of pregnant women in African region are anemic mainly due to iron deficiency.
Objectives: This study aimed to compare between the efficacy of amino acid chelated iron and iron polymaltose complex in treatment of iron deficiency anemia during pregnancy.
Patients and Methods: The study was done through giving anaemic pregnant women iron therapy in the form of amino acid chelated iron which represents group A arid iron polymaltose complex and it represents group B. For each pregnant woman, age, parity and gestational history were taken before treatment. All pregnant women took their allocated treatment regularly for eight weeks after diagnosis of iron deficiency anemia with hemoglobin level and serum ferritin level and followed up after four and eight weeks. Also, epigastric pain, diarrhea, constipation, nausea, vomiting or gastric distress reported to assess tolerability of the drugs.
Results: There was no significant difference between the two groups of therapy according to rise of haemoglobin, while serum ferritin level rise after 8 weeks of treatment, being more significant in the group of amino acid chelated iron. Incidence of side effects was more abundant in the group of amino acid chelated iron, but of no statistically significant difference. Also, there was no significant difference between the two groups in discontinuation of therapy.
Conclusion: Amino acid chelated iron and Iron polymaltose complex seem to increase Hb, but amino acid chelated iron increased serum ferritin levels more than iron polymaltose. The latter seems to produce less adverse effects than amino acid chelated iron as regards constipation, nausea, vomiting, abdominal pain and epigastric pain.